Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study
Abstract Objectives To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT). Methods In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02509-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Objectives To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT). Methods In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received dexmedetomidine (0.2–1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed. Results Doses ≥ 0.4 μg/kg (D2–D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4–D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2–D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays. Conclusions Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose. |
|---|---|
| ISSN: | 2047-783X |